Literature DB >> 19438238

Discovery of the first highly M5-preferring muscarinic acetylcholine receptor ligand, an M5 positive allosteric modulator derived from a series of 5-trifluoromethoxy N-benzyl isatins.

Thomas M Bridges1, Joy E Marlo, Colleen M Niswender, Carrie K Jones, Satyawan B Jadhav, Patrick R Gentry, Hyekyung C Plumley, C David Weaver, P Jeffrey Conn, Craig W Lindsley.   

Abstract

This report describes the discovery and initial characterization of the first positive allosteric modulator of muscarinic acetylcholine receptor subtype 5 (mAChR5 or M5). Functional HTS, identified VU0119498, which displayed micromolar potencies for potentiation of acetylcholine at M1, M3, and M5 receptors in cell-based Ca(2+) mobilization assays. Subsequent optimization led to the discovery of VU0238429, which possessed an EC(50) of approximately 1.16 microM at M5 with >30-fold selectivity versus M1 and M3, with no M2 or M4 potentiator activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19438238      PMCID: PMC3875304          DOI: 10.1021/jm900286j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice.

Authors:  M Yamada; K G Lamping; A Duttaroy; W Zhang; Y Cui; F P Bymaster; D L McKinzie; C C Felder; C X Deng; F M Faraci; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

2.  Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.

Authors:  Joy E Marlo; Colleen M Niswender; Emily L Days; Thomas M Bridges; Yun Xiang; Alice L Rodriguez; Jana K Shirey; Ashley E Brady; Tasha Nalywajko; Qingwei Luo; Cheryl A Austin; Michael Baxter Williams; Kwangho Kim; Richard Williams; Darren Orton; H Alex Brown; Craig W Lindsley; C David Weaver; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2008-12-01       Impact factor: 4.436

3.  Identification of a family of muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; N J Buckley; A C Young; M R Brann
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

4.  Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice.

Authors:  Runa Araya; Takanori Noguchi; Munehiro Yuhki; Naohito Kitamura; Makoto Higuchi; Takaomi C Saido; Kenjiro Seki; Shigeyoshi Itohara; Masako Kawano; Kentaro Tanemura; Akihiko Takashima; Kazuyuki Yamada; Yasushi Kondoh; Iwao Kanno; Jürgen Wess; Masahisa Yamada
Journal:  Neurobiol Dis       Date:  2006-09-07       Impact factor: 5.996

Review 5.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Authors:  Jürgen Wess; Richard M Eglen; Dinesh Gautam
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

6.  Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes.

Authors:  T I Bonner; A C Young; M R Brann; N J Buckley
Journal:  Neuron       Date:  1988-07       Impact factor: 17.173

Review 7.  Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications.

Authors:  Jürgen Wess
Journal:  Annu Rev Pharmacol Toxicol       Date:  2004       Impact factor: 13.820

8.  Deletion of the M5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia.

Authors:  Anthony S Basile; Irina Fedorova; Agustin Zapata; Xiaoguang Liu; Toni Shippenberg; Alokesh Duttaroy; Masahisa Yamada; Jurgen Wess
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-01       Impact factor: 11.205

Review 9.  Muscarinic acetylcholine receptors as CNS drug targets.

Authors:  Christopher J Langmead; Jeannette Watson; Charlie Reavill
Journal:  Pharmacol Ther       Date:  2007-12-20       Impact factor: 12.310

Review 10.  Allosterism at muscarinic receptors: ligands and mechanisms.

Authors:  N J M Birdsall; S Lazareno
Journal:  Mini Rev Med Chem       Date:  2005-06       Impact factor: 3.862

View more
  44 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

2.  Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.

Authors:  Evan P Lebois; Thomas M Bridges; L Michelle Lewis; Eric S Dawson; Alexander S Kane; Zixiu Xiang; Satyawan B Jadhav; Huiyong Yin; J Phillip Kennedy; Jens Meiler; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; C David Weaver; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2010       Impact factor: 4.418

Review 3.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 4.  The antipsychotic potential of muscarinic allosteric modulation.

Authors:  Thomas M Bridges; Evan P LeBois; Corey R Hopkins; Michael R Wood; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  Drug News Perspect       Date:  2010-05

Review 5.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

6.  Novel allosteric effects of amiodarone at the muscarinic M5 receptor.

Authors:  Edward Stahl; John Ellis
Journal:  J Pharmacol Exp Ther       Date:  2010-03-26       Impact factor: 4.030

7.  Isatin replacements applied to the highly selective, muscarinic M1 PAM ML137: continued optimization of an MLPCN probe molecule.

Authors:  Bruce J Melancon; Michael S Poslusney; Patrick R Gentry; James C Tarr; Douglas J Sheffler; Margrith E Mattmann; Thomas M Bridges; Thomas J Utley; J Scott Daniels; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Michael R Wood
Journal:  Bioorg Med Chem Lett       Date:  2012-12-01       Impact factor: 2.823

Review 8.  Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Shaun R Stauffer
Journal:  ACS Chem Neurosci       Date:  2011-06-27       Impact factor: 4.418

9.  Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.

Authors:  Thomas M Bridges; J Phillip Kennedy; Hyekyung P Cho; Micah L Breininger; Patrick R Gentry; Corey R Hopkins; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2009-11-22       Impact factor: 2.823

10.  A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning.

Authors:  Jana K Shirey; Ashley E Brady; Paulianda J Jones; Albert A Davis; Thomas M Bridges; J Phillip Kennedy; Satyawan B Jadhav; Usha N Menon; Zixiu Xiang; Mona L Watson; Edward P Christian; James J Doherty; Michael C Quirk; Dean H Snyder; James J Lah; Allan I Levey; Michelle M Nicolle; Craig W Lindsley; P Jeffrey Conn
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.